JNJJohnson & Johnson
Price
+40%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Johnson & Johnson (JNJ) reported revenue of $25.4B in Q3 2026 (quarter ended Sep 27, 2026), up 5.9% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $210M (0.8% of revenue). For the full year FY2025, revenue was $94.2B (+6.0% year on year) and net income $26.8B. Its largest product in Q2 2026 (quarter ended Jun 28, 2026) was DARZALEX at $2.44B, 19% of the disclosed total, ahead of Tremfya at 11%. The next results filing is expected around Jan 20, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 13, 2026Johnson & Johnson reports Q3 2026 results, raises 2026 guidance.Earnings release · press release
- Aug 4, 2026On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.Director or officer change · Form 8-K
- Jul 29, 2026J&J Global Media Relations.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $13.00BThe company’s own SEC segment disclosure.
- DARZALEX$2.44B19%
- Tremfya$1.47B11%
- INVEGASUSTENNAXEPLIONTRINZATREVICTA$738.0M6%
- Xarelto$664.0M5%
- GENERAL$596.0M5%
- TRAUMA$536.0M4%
- Other (27)$6.57B51%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry